Hong Kong Luxury Stock News

Logan Group (SEHK:3380) is back in the spotlight after moving past the halfway mark on its RMB13.66 billion onshore debt restructuring. More than 62% of public bond principal is now covered by new arrangements. See our latest analysis for Logan Group. The restructuring progress seems to be changing how investors price in Logan Group’s risk, with a strong 90 day share price return of 71.74% and a 1 year total shareholder return of 41.07% hinting that momentum is rebuilding after years of heavy...

New World Development has recently completed its debt exchange offer, issuing about US$1.36 billion in new bonds and cutting roughly US$1.17 billion of existing obligations, nearly halving the targeted portion of its debt load. This sizeable balance sheet adjustment could ease future interest costs and gives investors a clearer view of the company's efforts to manage its high leverage. We will now examine how this large debt reduction reshapes New World Development's investment narrative,...

Lepu Biopharma (SEHK:2157) just signed a GLP-1 focused CDMO framework deal with related party Lepu Medical, a move that could turn spare manufacturing capacity into recurring cashflow and reshape how investors think about its pipeline driven story. See our latest analysis for Lepu Biopharma. The 1 day share price return of 3.0% to HK$5.76 comes after a volatile few months, with the 3 month share price return still down sharply. However, the year to date share price return and 1 year total...

Postal Savings Bank of China Co., Ltd. has approved a reshuffle of its board committees, declared an interim dividend of RMB 1.23 per 10 shares for the first half of 2025, and scheduled an extraordinary general meeting for December 19, 2025, to vote on profit distribution, remuneration, board authorization changes and a financial bond issuance plan. Together, the dividend announcement and governance adjustments highlight the bank’s focus on capital management, regulatory alignment and...

Ascletis Pharma (SEHK:1672) just flagged a major pipeline milestone, selecting its in house, AI optimized ASC37 oral triple peptide agonist for clinical development in obesity, with an FDA IND filing targeted for 2026. See our latest analysis for Ascletis Pharma. That R&D breakthrough lands after a wild run in the stock, with a 1 month share price return of 42.97 percent and a massive 1 year total shareholder return of 663.58 percent, suggesting momentum is still very much alive. If this kind...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

In late November 2025, SSY Group reported a series of approvals from China’s National Medical Products Administration for new and existing drugs, including treatments for overactive bladder, respiratory diseases, liver-related cholestasis and vitamin A supplementation. These clustered approvals, many classified as passing China’s consistency evaluation, underline SSY Group’s push to broaden its portfolio of higher-quality, regulated pharmaceutical products in its home market. We’ll examine...

In November 2025, Onewo Inc. (SEHK:2602) began repurchasing its own shares under a shareholder-approved mandate allowing buybacks of up to 115,649,292 H shares, or 10% of its issued share capital, using funds available under PRC and other applicable laws. This sizeable authorization gives management meaningful flexibility to retire shares, which can lift net asset value per share and earnings per share over time. We will now examine how the commencement of this sizeable share repurchase...

WuXi Biologics (Cayman) recently announced a Memorandum of Understanding with the Qatar Free Zones Authority to establish its first integrated CRDMO center in the Middle East, extending its global biologics development and manufacturing network into the region. By pairing its one-stop CRDMO capabilities in complex biologics with Qatar’s push to build a regional biotech hub, WuXi Biologics is positioning itself as an early infrastructure partner in shaping the Middle East’s biopharmaceutical...

Inspur Digital Enterprise Technology Limited has completed a follow-on equity offering of HK$493,728,200, issuing 67,634,000 new ordinary shares at HK$7.30 per share with a HK$0.0511 discount per share via a subsequent direct listing. This capital raise expands the company’s funding flexibility while modestly increasing the free float, factors that can reshape how investors view its balance between growth ambitions and ownership dilution. We’ll now examine how this follow-on equity offering,...

China Gas Holdings (SEHK:384) just posted weaker half year earnings, with both sales and net income down from a year ago. This puts the recent share price gains into sharper context for investors. See our latest analysis for China Gas Holdings. Even with that earnings setback, the share price has climbed to HK$8.39 and delivered a robust year to date share price return of 27.12%. The 1 year total shareholder return of 41.41% suggests momentum has been rebuilding as investors reassess the risk...

Key Insights The projected fair value for Galaxy Entertainment Group is HK$50.31 based on 2 Stage Free Cash Flow to...

China Construction Bank Corporation recently held an Extraordinary General Meeting where shareholders approved a 2025 interim H share cash dividend of RMB 1.858 per 10 shares and endorsed the appointment of Shi Jian as a non-executive director, subject to regulatory approval. The bank is also set to consider a charitable donation to support fire rescue and relief efforts in Hong Kong’s Tai Po District, underlining how capital returns to investors are being balanced with a broader social...

Shanghai Fudan Microelectronics Group (SEHK:1385) just pushed through a sweeping governance revamp at its second EGM, reshaping its Articles of Association, board composition, and committee structure in a bid to streamline oversight. See our latest analysis for Shanghai Fudan Microelectronics Group. Those governance upgrades land at a time when sentiment is already strong, with the latest share price at HK$39.86 and a powerful year to date share price return backing the story, even after a...

China Education Group Holdings Limited has released its full-year results for the year ended August 31, 2025, reporting sales of CNY 7,363 million, up from CNY 6,579 million, and net income of CNY 977 million compared with CNY 418 million a year earlier. The sharp improvement in net income, alongside higher basic earnings per share from continuing operations rising to CNY 0.3551, points to stronger profitability and more efficient operations across the group’s education portfolio. With this...

UBS recently initiated coverage on Shanghai Conant Optical with a Buy rating and highlighted the company as the world’s second-largest spectacle lens producer by volume in 2024. The broker also pointed to the company’s traditional lens business and emerging smartglasses segment as key drivers of its long-term earnings potential. With these growth drivers in focus, we’ll now explore how UBS’s new coverage shapes Shanghai Conant Optical’s broader investment narrative. Rare earth metals are an...

At its November 25, 2025 extraordinary general meeting, Shanghai MicroPort MedBot (Group) Co., Ltd. approved amendments to its Articles of Association and shareholder meeting rules while reshaping its board and board committees, including appointing Dr. Zhaohua Chang as chairperson and several new non-executive and independent non-executive directors. This governance overhaul, spanning refreshed leadership and reconfigured oversight committees, signals a potential recalibration of how the...

Bank of China (SEHK:3988) has just completed a sizeable RMB 60 billion issue of write down tier 2 bonds. The move is aimed squarely at shoring up capital and giving the balance sheet more strategic flexibility. See our latest analysis for Bank of China. Even with the share price easing 4.65% over the last week, Bank of China still carries a solid year to date share price return of around 16%. Its 1 year total shareholder return north of 30% suggests momentum is still broadly constructive as...

TransThera Sciences (Nanjing) SEHK:2617 has quietly delivered a sharp move over the past 3 months, climbing more than 200%, which naturally raises the question of what the market is now pricing in. See our latest analysis for TransThera Sciences (Nanjing). That surge sits on top of an already extraordinary year to date, with a 726.38% year to date share price return. This suggests investors are rapidly repricing TransThera’s risk and growth prospects, even as near term swings remain...

Robosense Technology Co., Ltd has released its third-quarter 2025 results, showing CNY 407.11 million in sales with a wider quarterly net loss of CNY 101.04 million, while nine‑month sales rose to CNY 1,190.31 million and net loss narrowed to CNY 252.02 million compared with the prior year. The mix of stable quarterly revenue, a larger single‑quarter loss, and improved nine‑month loss figures offers a nuanced view of how Robosense’s cost structure and growth efforts are affecting its path...

It's not a stretch to say that HM International Holdings Limited's ( HKG:8416 ) price-to-sales (or "P/S") ratio of 0.2x...

Following the solid earnings report from Great World Company Holdings Ltd ( HKG:8003 ), the market responded by bidding...

Tai Ping Carpets International Limited ( HKG:146 ) is about to trade ex-dividend in the next 4 days. The ex-dividend...

L.K. Technology Holdings Limited's ( HKG:558 ) recent weak earnings report didn't cause a big stock movement. However...